Adagene (NASDAQ: ADAG)
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
FY 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -1.360 | ||||||
REV | 10.175M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Adagene (NASDAQ: ADAG) through any online brokerage.
Other companies in Adagene’s space includes: OncoCyte (NASDAQ:OCX), Immuneering (NASDAQ:IMRX), Atossa Therapeutics (NASDAQ:ATOS), Finch Therapeutics Group (NASDAQ:FNCH) and Portage Biotech (NASDAQ:PRTG).
The latest price target for Adagene (NASDAQ: ADAG) was reported by Morgan Stanley on Tuesday, February 1, 2022. The analyst firm set a price target for 15.00 expecting ADAG to rise to within 12 months (a possible 431.91% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Adagene (NASDAQ: ADAG) is $2.82 last updated May 23, 2022, 8:00 PM UTC.
There are no upcoming dividends for Adagene.
Adagene’s H1 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for Adagene.
Adagene is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.